Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.87
HTWR's Cash to Debt is ranked higher than
63% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. HTWR: 1.87 )
HTWR' s 10-Year Cash to Debt Range
Min: 1.03   Max: No Debt
Current: 1.87

Equity to Asset 0.46
HTWR's Equity to Asset is ranked higher than
50% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. HTWR: 0.46 )
HTWR' s 10-Year Equity to Asset Range
Min: 0.33   Max: 0.91
Current: 0.46

0.33
0.91
F-Score: 6
Z-Score: 3.08
M-Score: -1.09
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -22.87
HTWR's Operating margin (%) is ranked higher than
50% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 6.25 vs. HTWR: -22.87 )
HTWR' s 10-Year Operating margin (%) Range
Min: -8846.69   Max: -22.87
Current: -22.87

-8846.69
-22.87
Net-margin (%) -28.52
HTWR's Net-margin (%) is ranked higher than
50% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. HTWR: -28.52 )
HTWR' s 10-Year Net-margin (%) Range
Min: -7157.83   Max: -28.52
Current: -28.52

-7157.83
-28.52
ROE (%) -29.86
HTWR's ROE (%) is ranked higher than
50% of the 365 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. HTWR: -29.86 )
HTWR' s 10-Year ROE (%) Range
Min: -128.6   Max: -17.52
Current: -29.86

-128.6
-17.52
ROA (%) -13.80
HTWR's ROA (%) is ranked higher than
54% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. HTWR: -13.80 )
HTWR' s 10-Year ROA (%) Range
Min: -86.09   Max: -10.99
Current: -13.8

-86.09
-10.99
ROC (Joel Greenblatt) (%) -104.49
HTWR's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 12.55 vs. HTWR: -104.49 )
HTWR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -736.7   Max: -81.47
Current: -104.49

-736.7
-81.47
Revenue Growth (%) 47.00
HTWR's Revenue Growth (%) is ranked higher than
98% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. HTWR: 47.00 )
HTWR' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 429.3
Current: 47

0
429.3
EBITDA Growth (%) 6.80
HTWR's EBITDA Growth (%) is ranked higher than
82% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. HTWR: 6.80 )
HTWR' s 10-Year EBITDA Growth (%) Range
Min: -16.8   Max: 35.3
Current: 6.8

-16.8
35.3
EPS Growth (%) 19.40
HTWR's EPS Growth (%) is ranked higher than
88% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: -2.80 vs. HTWR: 19.40 )
HTWR' s 10-Year EPS Growth (%) Range
Min: -15.5   Max: 42
Current: 19.4

-15.5
42
» HTWR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

HTWR Guru Trades in Q1 2013

Manning & Napier Advisors, Inc 159,420 sh (+0.06%)
Pioneer Investments Sold Out
Steven Cohen 163,900 sh (-32.41%)
» More
Q2 2013

HTWR Guru Trades in Q2 2013

Manning & Napier Advisors, Inc 205,990 sh (+29.21%)
Steven Cohen Sold Out
» More
Q3 2013

HTWR Guru Trades in Q3 2013

Steven Cohen 51,699 sh (New)
Manning & Napier Advisors, Inc 280,650 sh (+36.24%)
» More
Q4 2013

HTWR Guru Trades in Q4 2013

Paul Tudor Jones 5,715 sh (New)
Steven Cohen 219,800 sh (+325.15%)
Manning & Napier Advisors, Inc 282,710 sh (+0.73%)
» More
» Details

Insider Trades

Latest Guru Trades with HTWR

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2012-03-31 Sold Out 0.05%$65.86 - $75.83 $ 84.9829%0
George Soros 2011-12-31 Reduce -90%0.15%$58.78 - $70.56 $ 84.9830%15000
George Soros 2011-09-30 Add 900%0.15%$54.9 - $73.88 $ 84.9833%150000
George Soros 2011-06-30 New Buy0.02%$67 - $84.32 $ 84.9815%15000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.30
HTWR's P/B is ranked lower than
72% of the 355 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. HTWR: 7.30 )
HTWR' s 10-Year P/B Range
Min: 4.16   Max: 20.13
Current: 7.3

4.16
20.13
P/S 6.60
HTWR's P/S is ranked lower than
71% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. HTWR: 6.60 )
HTWR' s 10-Year P/S Range
Min: 5.83   Max: 130.95
Current: 6.6

5.83
130.95
EV-to-EBIT 6.70
HTWR's EV-to-EBIT is ranked higher than
93% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 20.91 vs. HTWR: 6.70 )
HTWR' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 6.7

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 132.80
HTWR's Price/Net Current Asset Value is ranked lower than
95% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 9.10 vs. HTWR: 132.80 )
HTWR' s 10-Year Price/Net Current Asset Value Range
Min: 7.36   Max: 466.39
Current: 132.8

7.36
466.39
Price/Tangible Book 16.80
HTWR's Price/Tangible Book is ranked lower than
84% of the 328 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. HTWR: 16.80 )
HTWR' s 10-Year Price/Tangible Book Range
Min: 5.99   Max: 20.68
Current: 16.8

5.99
20.68
Price/Median PS Value 0.50
HTWR's Price/Median PS Value is ranked higher than
95% of the 338 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. HTWR: 0.50 )
HTWR' s 10-Year Price/Median PS Value Range
Min: 0.57   Max: 1.7
Current: 0.5

0.57
1.7
Forward Rate of Return (Yacktman) 11.18
HTWR's Forward Rate of Return (Yacktman) is ranked higher than
90% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. HTWR: 11.18 )
HTWR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 15.7   Max: 30.2
Current: 11.18

15.7
30.2

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:HIN.Australia, X1H.Germany, HIY1.Germany
Heartware International, Inc., was incorporated in Delaware on July 29, 2008 and became the successor issuer to HeartWare Limited, an Australian corporation, on November 13, 2008, as a result of the Australian Court approved redomiciliation of HeartWare Limited from Australia to Delaware. HeartWare is a medical device company engaged in developing implantable blood pumps for the treatment of advanced heart failure. The Company operates one reportable segment which includes the design, manufacture and marketing of medical devices for the treatment of advanced heart failure. The HeartWare Ventricular Assist System, which includes a left ventricular assist device, or blood pump, patient accessories and surgical tools, is designed to provide circulatory support for patients with advanced heart failure. Beyond the HeartWare System, the company is also evaluating its next device, the Miniaturized Ventricular Assist Device. The MVAD is based on the same technology platform as the HeartWare System but adopts an axial flow, rather than a centrifugal flow, configuration and is being developed in multiple configurations. The MVAD designs are currently at the preclinical stage and undergoing animal studies focused on minimally invasive implantation techniques and are each approximately one-third the size of the HVAD Pump. HEARTWARE, HVAD and MVAD, KRITON and various company logos are the trademarks of the Company, in the United States, Australia and other countries.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide